The world’s first! British approved oral anti-new crown drug
On November 5, according to Law, London reported on November 4th, the British Drug and Health Products Authority (MHRA) announced that the anti-viral drug developed by Merck on Thursday is used to treat mild to moderate neoguanpneumitis. patient. The British Health Minister Saiside Jaweid said: Today is a historic day for our country, because the UK is now the world’s first approval of the country to treat new coronary pneumonia antiviral drugs.
He also said: For the most vulnerable and immunosuppressed groups, this will change the rules of the game, they will soon accept this breakthrough treatment. According to the report, the mechanism of action mechanisms called Molnupiravir’s antiviral drugs is to reduce the replication capabilities of the virus, thereby delaying the development speed of the disease. The British Drug and Health Products Authority said that the conclusion in clinical trials is that it is safe and effective in reducing the risk of being in hospital or death in patients with severe intensity.
The report pointed out that according to clinical trial data, this drug is most effective in the initial period of infection, so the British Drug and Health Products Authority recommends it within 5 days of symptoms.
The report also pointed out that it was approved for patients with at least one of a severe risk factor, including obesity, elderly, diabetes and heart disease. One of the most affected countries affected by the epidemic, UK announced on October 20 that it has ordered 480,000 dosage Monabiiwei to the US Pharmaceutical Giant Merke.